reports
- Robert Jan Vos
Ageas successfully places its inaugural GBP 400 million Senior Notes
Ageas successfully places its inaugural GBP 400 million Senior Notes Today ageas SA/NV successfully placed its inaugural debt securities in the form of GBP 400 million Senior Fixed Rate Notes (the “Notes”) maturing in December 2028 and with a first call date in September 2028. The issuance generated substantial interest from UK institutional investors. The Notes will be issued in denominations of GBP 100,000 at a re-offer price of 99.963 with a fixed coupon rate of 4.75% payable annually, with a first coupon payment scheduled for December 2025. Standard and Poor's assigned an A+ rating an...
Ageas annonce le succès du placement de ses premiers GBP 400 millions ...
Ageas annonce le succès du placement de ses premiers GBP 400 millions de dettes de premier rang Aujourd’hui, ageas SA/NV a réalisé, avec succès, le placement de ses premiers titres de dette sous la forme de GBP 400 millions d’obligations Senior subordonnées à taux fixe (les « titres ») arrivant à échéance en décembre 2028, avec une première date de remboursement en septembre 2028. L’émission a suscité un intérêt considérable des investisseurs institutionnels au Royaume-Uni. Les titres seront émis en coupures de GBP 100.000 à un prix de réémission de 99,963 avec un taux de coupon fixe de...
Ageas plaatst met succes zijn eerste GBP 400 miljoen aan Senior Notes
Ageas plaatst met succes zijn eerste GBP 400 miljoen aan Senior Notes Ageas SA/NV plaatste vandaag met succes zijn eerste schuldeffecten in de vorm van GBP 400 miljoen Senior Fixed Rate Notes (de “Notes”), met vervaldag in december 2028 en eerste call date in september 2028. De uitgifte kon rekenen op veel belangstelling van institutionele investeerders in het Verenigd Koninkrijk. De Notes zullen uitgegeven worden in coupures van GBP 100.000 aan een heruitgifteprijs van 99,963 en met een vaste couponrente van jaarlijks 4,75 %, met een eerste uitbetaling in december 2025. Standard & Poor’...
Moody's Ratings assigns A1 rating to ageas SA/NV's GBP400 million seni...
Louis Nonchez AVP-Analyst Benjamin Serra Senior Vice President Releasing Office : Moody's France SAS 21 Boulevard Haussmann Paris, 75009 France JOURNALISTS : 44 20 7772 5456 Client Service : 44 20 7772 5454 Paris , June 24, 2025 - Moody's Ratings (Moody's) has today assigned an A1 rating to the £...
- Carole Braudeau
- Carole Braudeau
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 82,223 Ageas shares in the period from 16-06-2025 until 20-06-2025. Date Number ofShares Total amount(EUR) Average price(EUR) Lowest price(EUR) Highest price(EUR) 16-06-2025 4,440 250,826 56.49 56.35 56.65 17-06-2025 27,845 1,565,455 56.22 55.90 56.40 18-06-2025 14,450 814,241 56.35 56.10 56.45 19-06-2025 20,800 1,168,272 56.17 56.05 56.35 20-06-2025 14,688 838,003 57.05...
Rapport d’Ageas sur le programme de rachat d’actions
Rapport d’Ageas sur le programme de rachat d’actions COMMUNIQUÉ DE PRESSE Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que 82.223 actions Ageas ont été achetées durant la période du 16-06-2025 au 20-06-2025. Date Nombred’actions Montant total(EUR) Cours moyen(EUR) Cours le plus bas (EUR) Cours le plus élevé (EUR) 16-06-2025 4.440 250.826 56,49 56,35 56,65 17-06-2025 27.845 1.565.455 56,22 55,90 56,40 18-06-2025 14.450 814.241 56,35 56,10 56,45 19-06-2025 20.800 1.168.272 56,17 56,05 56,35 20-06-2025 14....
Ageas rapporteert over de inkoop van eigen aandelen
Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 82.223 eigen aandelen ingekocht werden tussen 16-06-2025 en 20-06-2025. Datum Aantalaandelen Totaal Bedrag(EUR) Gemiddelde koers(EUR) Laagste koers(EUR) Hoogste koers(EUR) 16-06-2025 4.440 250.826 56,49 56,35 56,65 17-06-2025 27.845 1.565.455 56,22 55,90 56,40 18-06-2025 14.450 814.241 56,35 56,10 56,45 19-06-2025 20.800 1.168.272 56,17 56,05 56,35 20-06-2025 14.688 838.003 57,...
- Jacob Mekhael
Galapagos Appoints Aaron Cox as new CFO
Galapagos announced the appointment of Aaron Cox as CFO, effective 7 July 2025. Most recently, he served as Executive VP and CFO at Horizon Therapeutics. Aaron replaces Thad Huston, who joined Galapagos as CFO in 2023. With plans to explore strategic options for the cell therapy business, as well as plans to utilise the €3.3b cash (as of 1Q25) to build a new pipeline through business development, Aaron's network and experience in deal making will be key to Galapagos' strategy going forward. We r...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
Galapagos benoemt Aaron Cox als Chief Financial Officer
Galapagos benoemt Aaron Cox als Chief Financial Officer Voormalig CFO van Horizon vervoegt Galapagos met diepgaande expertise in internationale bedrijfsfinanciering, fusies en overnames, bedrijfsontwikkeling en strategisch leiderschap Mechelen, België; 23 juni 2025, 07:30 CET; gereglementeerde informatie - voorwetenschap - Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de benoeming aan van de heer Aaron Cox als Chief Financial Officer, met ingang van 7 juli 2025. De heer Cox volgt de heer Thad Huston op, die tot 31 juli 2025 bij het bedrijf zal blijven om een soepele overdracht t...
Galapagos Appoints Aaron Cox as Chief Financial Officer
Galapagos Appoints Aaron Cox as Chief Financial Officer Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Aaron Cox as Chief Financial Officer, effective July 7, 2025. Mr. Cox succeeds Mr. Thad Huston, who will remain with the company through July 31, 2025, to ensure a smooth transition of responsibilities.Aaron brings more than two ...
Galapagos NV: 1 director
A director at Galapagos NV bought 5,129 shares at 28.300EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Jacob Mekhael
Galapagos GLPG5101 phase 1/2 r/r iNHL cohort differentiates with high ...
Galapagos presented new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the International Conference on Malignant Lymphoma (ICML). Results from the r/r iNHL cohort (FL and MZL) showed a high complete response rate of 97%, higher than Yescarta's 75% CR rate (79% in FL, 75% in MZL) in the same patient population in the phase 2 (ZUMA-5) trial. Safety continues to be a differentiator with only 1 grade 3 ICANS (vs. 19% grade = 3 with Yescarta). All in all, a supportive ...
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 ...
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing GLPG5101 demonstrated promising efficacy with durable CAR-T cell persistence and a favorable safety profile, including a 97% complete response rate, 100% MRD negativity in evaluable patients, su...
Galapagos presenteerde nieuwe gegevens op ICML 2025 van Cohort 3 van d...
Galapagos presenteerde nieuwe gegevens op ICML 2025 van Cohort 3 van de ATALANTA-1 studie bij patiënten met recidief/refractair indolent NHL, en toonde hoge complete respons- en MRD-negativiteitspercentages aan met de CAR-T-kandidaat GLPG51 Van de 34 patiënten die werden ingeschreven in Cohort 3 van de ATALANTA-1 fase 1/2-studie, ontvingen er 32 GLPG5101; 94% kreeg verse CAR T-cellen toegediend, en 93% werd behandeld binnen zeven dagen na productie GLPG5101 toonde veelbelovende werkzaamheid met een langdurige CAR T-cel persistentie en een gunstig veiligheidsprofiel, waaronder 97% complete...
- Guy Sips
- Kristof Samoy
- Livio Luyten
- Thomas Vranken
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.